玛瓦卡姆特治疗症状性非梗阻性肥厚型心肌病
这项3期国际双盲安慰剂对照试验纳入症状性非梗阻性肥厚型心肌病成人患者,按1:1随机分配接受玛瓦卡姆特(起始5 mg/日,根据左心室射血分数调整至最大15 mg/日)或安慰剂治疗48周。主要终点为峰值摄氧量和KCCQ-CSS较基线的变化,两组间差异均未达统计学显著。
要点
- 玛瓦卡姆特组与安慰剂组48周峰值摄氧量变化差异为0.47 ml/kg/min(95%CI -0.03至0.98;P=0.07),未达统计学显著。
- 玛瓦卡姆特组与安慰剂组48周KCCQ-CSS变化差异为2.7分(95%CI -0.1至5.6;P=0.06),未达统计学显著。
- 玛瓦卡姆特组射血分数降低和试验方案中断较安慰剂组更常见。
核心结论
- 在非梗阻性肥厚型心肌病患者中,玛瓦卡姆特较安慰剂未显著改善峰值摄氧量或更有效减轻症状。
研究设计与样本
- 3期、国际、双盲、安慰剂对照临床试验。
- 纳入症状性非梗阻性肥厚型心肌病成人患者,随机分配至玛瓦卡姆特组289例和安慰剂组291例。
- 玛瓦卡姆特起始5 mg/日,根据左心室射血分数调整至最大15 mg/日;安慰剂组进行模拟剂量调整;治疗48周。
- 患者平均(±SD)年龄56±15岁,女性占46%。
主要发现
- 峰值摄氧量从基线至第48周的最小二乘均值变化:玛瓦卡姆特组0.52 ml/kg/min(95%CI 0.09至0.95),安慰剂组0.05 ml/kg/min(95%CI -0.38至0.47);组间差异0.47 ml/kg/min(95%CI -0.03至0.98;P=0.07)。
- KCCQ-CSS从基线至第48周的最小二乘均值变化:玛瓦卡姆特组13.1分(95%CI 10.7至15.5),安慰剂组10.4分(95%CI 8.0至12.8);组间差异2.7分(95%CI -0.1至5.6;P=0.06)。
- 射血分数降低和试验方案中断在玛瓦卡姆特组较安慰剂组更常见。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain. METHODS: We conducted a phase 3, international, double-blind, placebo-controlled, clinical trial to determine whether mavacamten improves functional capacity and patient-reported health status among adults with symptomatic nonobstructive HCM. Patients were randomly assigned in a 1:1 ratio to receive mavacamten (starting at 5 mg per day and adjusted up to a maximum of 15 mg per day on the basis of left ventricular ejection fraction) or placebo (with sham dose adjustment) for 48 weeks. The two primary end points were the change from baseline to week 48 in peak oxygen uptake and in the 23-item Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better health status). RESULTS: We randomly assigned 289 patients to receive mavacamten and 291 to receive placebo. The mean (±SD) age of the patients was 56±15 years, and 46% were women. From baseline to week 48, the least-squares mean change in peak oxygen uptake was 0.52 ml per kilogram of body weight per minute (95% confidence interval [CI], 0.09 to 0.95) in the mavacamten group and 0.05 ml per kilogram per minute (95% CI, -0.38 to 0.47) in the placebo group (between-group difference, 0.47 ml per kilogram per minute; 95% CI, -0.03 to 0.98; P = 0.07). The least-squares mean change in the KCCQ-CSS was 13.1 points (95% CI, 10.7 to 15.5) in the mavacamten group and 10.4 points (95% CI, 8.0 to 12.8) in the placebo group (between-group difference, 2.7 points; 95% CI, -0.1 to 5.6; P = 0.06). Reductions in ejection fraction and interruptions in the trial regimen were more common with mavacamten than with placebo. CONCLUSIONS: Among patients with nonobstructive HCM, mavacamten did not result in a significantly greater improvement in peak oxygen uptake or decrease in symptoms than placebo. (Funded by Bristol Myers Squibb; ODYSSEY-HCM ClinicalTrials.gov number, NCT05582395.).
引用
- Desai MY, Owens AT, Abraham T, et al. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025. PMID: 40888717. doi:10.1056/NEJMoa2505927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。